If you’re interested in companies that are involved in the fight against cancer, you may be interested in this list.
We ran a screen on healthcare companies that are involved in treating or researching cancer. We screened these companies for those seeing significant net insider buying over the last six months.
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.
We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.
click on image to enlarge
Do you think insiders are calling it right on these companies? Use this list as a starting-off point for your own analysis.
List sorted by net insider purchases as a percent of share float:
- Opko Health, Inc. (OPK): Medical Appliances & Equipment Industry. Market cap of $1.12B. Net insider purchases over the last six months at 6.85M, which is 44.51% of the company's 15.40M share float. The stock is a short squeeze candidate, with a short float at 8.33% (equivalent to 9.88 days of average volume). The stock has had a couple of great days, gaining 7.73% over the last week. The stock has performed poorly over the last month, losing 10.96%.
- GTX Inc. (GTXI): Biotechnology Industry. Market cap of $179.55M. Net insider purchases over the last six months at 6.98M, which is 33.09% of the company's 21.09M share float. The stock is a short squeeze candidate, with a short float at 13.06% (equivalent to 7.62 days of average volume). The stock has had a couple of great days, gaining 27.34% over the last week. The stock has performed poorly over the last month, losing 17.87%.
- Tengion, Inc. (TNGN): Medical Laboratories & Research Industry. Market cap of $27.86M. Net insider purchases over the last six months at 2.47M, which is 26.86% of the company's 9.21M share float. The stock has had a couple of great days, gaining 17% over the last week. The stock has performed poorly over the last month, losing 10.69%.
- Anadys Pharmaceuticals Inc. (ANDS): Biotechnology Industry. Market cap of $42.89M. Net insider purchases over the last six months at 5.41M, which is 20.85% of the company's 25.92M share float. The stock has had a couple of great days, gaining 13.64% over the last week. The stock has performed poorly over the last month, losing 25%.
- Complete Genomics, Inc. (GNOM): Biotechnology Industry. Market cap of $276.25M. Net insider purchases over the last six months at 1.65M, which is 18.25% of the company's 9.04M share float. The stock is a short squeeze candidate, with a short float at 6.58% (equivalent to 5.3 days of average volume). The stock has performed poorly over the last month, losing 44.04%.
- AMAG Pharmaceuticals, Inc. (AMAG): Diagnostic Substances Industry. Market cap of $310.01M. Net insider purchases over the last six months at 991.15K, which is 7.64% of the company's 12.98M share float. The stock is a short squeeze candidate, with a short float at 9.03% (equivalent to 5.55 days of average volume). The stock has performed poorly over the last month, losing 23.28%.
- ZIOPHARM Oncology, Inc. (ZIOP): Biotechnology Industry. Market cap of $343.37M. Net insider purchases over the last six months at 4.34M, which is 7.39% of the company's 58.64M share float. The stock is a short squeeze candidate, with a short float at 10.8% (equivalent to 10.79 days of average volume). The stock has performed poorly over the last month, losing 15.63%.
- Threshold Pharmaceuticals Inc. (THLD): Biotechnology Industry. Market cap of $65.74M. Net insider purchases over the last six months at 1.97M, which is 7.07% of the company's 27.81M share float. The stock is currently stuck in a downtrend, trading 15.97% below its SMA20, 22.02% below its SMA50, and 22.81% below its SMA200. The stock has had a couple of great days, gaining 7.2% over the last week. The stock has performed poorly over the last month, losing 34.95%.
- Synta Pharmaceuticals Corp. (SNTA): Diagnostic Substances Industry. Market cap of $198.0M. Net insider purchases over the last six months at 1.55M, which is 5.12% of the company's 30.19M share float. This is a risky stock that is significantly more volatile than the overall market (beta = 2.5). The stock is a short squeeze candidate, with a short float at 8.72% (equivalent to 15.21 days of average volume). The stock has had a couple of great days, gaining 8.7% over the last week.
- MannKind Corp. (MNKD): Biotechnology Industry. Market cap of $336.59M. Net insider purchases over the last six months at 3.48M, which is 4.38% of the company's 79.46M share float. The stock is a short squeeze candidate, with a short float at 26.11% (equivalent to 23.57 days of average volume). The stock has had a couple of great days, gaining 14.22% over the last week. The stock has performed poorly over the last month, losing 29.97%.
- Ardea Biosciences, Inc. (RDEA): Drug Manufacturers Industry. Market cap of $398.78M. Net insider purchases over the last six months at 495.55K, which is 2.17% of the company's 22.88M share float. The stock is a short squeeze candidate, with a short float at 6.26% (equivalent to 13.62 days of average volume). The stock has performed poorly over the last month, losing 37.97%.
- Genomic Health Inc. (GHDX): Medical Laboratories & Research Industry. Market cap of $721.92M. Net insider purchases over the last six months at 554.75K, which is 2.07% of the company's 26.75M share float. The stock is a short squeeze candidate, with a short float at 9.46% (equivalent to 20.4 days of average volume). The stock has performed poorly over the last month, losing 13.74%.
*Insider data sourced from Yahoo Finance, all other data sourced from Finviz.
